Medical News

RSS

American Red Cross of Greater Cleveland to conduct Operation Save-A-Life Fire Safety Walk

In response to the recent deaths from multiple house fires in the City of Cleveland, The American Red Cross of Greater Cleveland in partnership with the City of Cleveland Fire Department, is conducting an Operation Save-A-Life Fire Safety Walk on the near west-side of Cleveland on Monday, November 23, 2009.

23 Nov 2009

Marriott UMUC's initiative to collect funds for Children’s Miracle Network

Armed with $5 bills, the shoppers lined up waiting for the doors to open. Sound like some kind of bizarre sale? This was no sale, it was the scene at the opening of the temporary thrift store at Marriott’s University of Maryland University College Inn and Conference Center. Local community members in need were invited to stuff as many clothes as they could into shopping bags for $5 a bag. All proceeds went to the Children’s Miracle Network (CMN).

23 Nov 2009

RXi Pharmaceuticals receives prestigious Innovation of the Year Award

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan’s 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.

23 Nov 2009

New FluCide better than the older version

NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

23 Nov 2009

Most Canadians hope OAB symptoms will go away

A recent poll conducted by Leger Marketing, on behalf of the Powder Room - a national education program for those with overactive bladder (OAB) - asked 1,500 Canadians about their bladder health. The findings revealed that although people are experiencing OAB symptoms, most are choosing not to seek medical attention - perhaps assuming the frustrating and embarrassing symptoms will go away, or that they will just have to live with them.

23 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

Verizon launches telehealth services

Time, distance and cost often hamper efforts to link patients with the right health care expert, causing further concern for those needing to consult with faraway doctors. Verizon is answering this need with new services for physicians, hospitals, clinics and insurers that enable providers to "see" patients through video consultations, as well as other collaboration services.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

First Edition: November 23, 2009

Today's headlines indicate that even after Senate Majority Leader Harry Reid found victory Saturday night with the first health bill test vote, his measure is likely to be the subject of an even more intense debate as the measure moves forward.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.

23 Nov 2009

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Aesthetic Plastic Surgery: The Next Generation Symposium will be held from December 4-6 at the Waldorf Astoria, announces Z. Paul Lorenc, MD, FACS, New York aesthetic plastic surgeon and Chairman of the APSSNY.

23 Nov 2009

Cellular prion protein and epileptic seizures: researchers find new role

Cellular prion protein (PrPc) plays an essential role in maintaining neurotransmitter homeostasis in the central nervous system. This discovery has been made possible by the observation that both a deficiency and an excess of the protein have a considerable effect on this homeostasis.

23 Nov 2009

MedPro Safety Products updates on its recent progress

MedPro Safety Products, Inc., a pioneer in the development and marketing of passive needlestick injury prevention technology, today reported on the Company’s recent progress.

23 Nov 2009

STD infections continue to rise among young people

Sexually spread diseases continue to rise, with reported chlamydia cases setting yet another record in 2008, officials at the Centers for Disease Control recently reported. The CDC estimates that approximately 19 million new STD infections occur each year. Approximately half of them occur in young people between 15 to 24 years of age.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.

23 Nov 2009

Enrollment for ongoing phase 2b trial of RG7128 announced

Pharmasset, Inc. announced today that the enrollment of Cohort 2, led by its partner Roche, will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

23 Nov 2009